Giant osteoclasts after long-term bisphosphonate therapy: Diagnostic challenges

Nature Reviews Rheumatology

Volumn 5, Issue 6, 2009, Pages 341-346

  Jain, Nidhi ^a   Weinstein, Robert S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

CASE REPORT; FEMALE; HUMAN; MEDICAL EDUCATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOPOROSIS; PATHOLOGY; REVIEW; SPINE FRACTURE;

ADMINISTRATION, ORAL; DIPHOSPHONATES; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; SPINAL FRACTURES;

EID: 68849125510     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.87     Document Type: Article

References (17)

1. Liberman, U. et al. effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333, 1437-1443 (1995).
2. Bone, H. G. et al. dose-response relationships for alendronate treatment in osteoporotic elderly women. J. Clin. Endocrinol. Metab. 82, 265-274 (1997).
3. Mcclung, M. et al. alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann. Intern. Med. 128, 253-261 (1998).
4. Reid, I. R. et al. alendronate in Paget's disease. Am. J. Med. 101, 341-348 (1996).
5. Saag, K. G. et al. alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention study Group. N. Engl. J. Med. 339, 292-299 (1998).
6. Orwoll, E. et al. alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604-610 (2000).
7. Russell, R. G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119 (Suppl. 2), s150-s162 (2007).
8. Rogers, M. J. et al. cellular and molecular mechanisms of action of bisphosphonates. Cancer 88, 2961-2978 (2000).
9. Fleisch, H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 4th edn 42 (academic, san diego, 2000).
10. Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53-62 (2009).
11. Spjut, H. J., dorfman, H. D., Fechner, R. E. & ackermann, L. V. Atlas of Tumor Pathology, Second Aeries, Fascicle 5: Tumors of Bone and Cartilage (armed Forces Institute of Pathology, Washington, dc, 1971).
12. Whyte, M. P., Wenkert, D., clements, K. L., Mcalister, W. H. & Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457-463 (2003).
13. Rauch, F., travers, R., Plotkin, H. & Glorieux, F. H. the effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J. Clin. Invest. 110, 1293-1299 (2002).
14. Dempster, D. W. et al. unusual osteoclast morphology in teriparatide-treated patients who have been pretreated with alendronate. J. Bone Miner. Res. 22 (Suppl. 1), s29 (2007).
15. Muche B. et al. Bisphosphonates in male osteoporosis-long-term histomorphologic changes. J. Bone Miner. Res. 18 (Suppl. 2), s371 (2003).
16. Singer, R. S. Paget's Disease of Bone (Plenum Medical Book company, New york, 1977).
17. Weinstein, R. S. chapter 20: the clinical use of Bone Biopsy. In Disorders of Bone and Mineral Metabolism, 2nd edn (eds coe, F. L. & Favus, M. J.) 448-468 (Raven, New york, 2002).